OptiTope—a web server for the selection of an optimal set of peptides for epitope-based vaccines

Epitope-based vaccines (EVs) have recently been attracting significant interest. They trigger an immune response by confronting the immune system with immunogenic peptides derived from, e.g. viral- or cancer-related proteins. Binding of these peptides to proteins from the major histocompatibility complex (MHC) is crucial for immune system activation. However, since the MHC is highly polymorphic, different patients typically bind different repertoires of peptides. Furthermore, economical and regulatory issues impose strong limitations on the number of peptides that can be included in an EV. Hence, it is crucial to identify the optimal set of peptides for a vaccine, given constraints such as MHC allele probabilities in the target population, peptide mutation rates and maximum number of selected peptides. OptiTope aims at assisting immunologists in this critical task. With OptiTope, we provide an easy-to-use tool to determine a provably optimal set of epitopes with respect to overall immunogenicity in a specific individual (personalized medicine) or a target population (e.g. a certain ethnic group). OptiTope is available at http://www.epitoolkit.org/optitope.

[1]  Oliver Kohlbacher,et al.  SVMHC: a server for prediction of MHC-binding peptides , 2006, Nucleic Acids Res..

[2]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[3]  Chee Keong Kwoh,et al.  Hotspot Hunter: a computational system for large-scale screening and selection of candidate immunological hotspots in pathogen proteomes , 2008, BMC Bioinformatics.

[4]  Oliver Kohlbacher,et al.  EpiToolKit—a web server for computational immunomics , 2008, Nucleic Acids Res..

[5]  Yoram Louzoun,et al.  Virus-epitope vaccine design: informatic matching the HLA-I polymorphism to the virus genome. , 2007, Molecular immunology.

[6]  A. Vitiello,et al.  The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. , 1994, Journal of immunology.

[7]  O. Lund,et al.  NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence , 2007, PloS one.

[8]  James Theiler,et al.  Web-based design and evaluation of T-cell vaccine candidates , 2008, Bioinform..

[9]  James McCluskey,et al.  More than one reason to rethink the use of peptides in vaccine design , 2007, Nature Reviews Drug Discovery.

[10]  Oliver Kohlbacher,et al.  A Mathematical Framework for the Selection of an Optimal Set of Peptides for Epitope-Based Vaccines , 2008, PLoS Comput. Biol..

[11]  Anne S De Groot,et al.  HIV vaccine development by computer assisted design: the GAIA vaccine. , 2005, Vaccine.

[12]  Steve Wilson,et al.  The Immune Epitope Database and Analysis Resource: From Vision to Blueprint , 2005, PLoS biology.

[13]  Leonard Moise,et al.  Prediction of immunogenicity for therapeutic proteins: state of the art. , 2007, Current opinion in drug discovery & development.

[14]  K. Parker,et al.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.

[15]  Gajendra P. S. Raghava,et al.  ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..